Cite
HARVARD Citation
Inzucchi, S. et al. (2022). Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 10 (12), pp. 869-881. [Online].